Characteristics | Before PSM (N = 939) | After PSM (N = 603) | ||||
---|---|---|---|---|---|---|
PLD group (N = 292) | Epirubicin group (N = 647) | P value | PLD group (N = 201) | Epirubicin group (N = 402) | P value | |
Age (year), n (%) | Â | Â | 0.0262 | Â | Â | 1.0000 |
  < 35 | 14 (4.8%) | 58 (9.0%) |  | 10 (5.0%) | 20 (5.0%) |  |
  ≥ 35 | 278 (95.2%) | 589 (91.0%) |  | 191 (95.0%) | 382 (95.0%) |  |
Age (year), Median (range) | 48 (25,70) | 49 (23,70) | 0.8529 | 49 (42–56) | 50 (44–56) | 0.7495 |
Menopausal status, n (%) | Â | Â | 0.2343 | Â | Â | 0.6739 |
 Premenopausal | 115 (39.4%) | 242 (37.4%) |  | 105 (52.2%) | 228 (56.7%) |  |
 Postmenopausal | 153 (52.4%) | 384 (59.4%) |  | 80 (39.8%) | 161 (40.1%) |  |
 Missing | 24 (8.2%) | 21 (3.3%) |  | 16 (8.0%) | 13 (3.2%) |  |
Histological grade, n (%) | Â | Â | 0.9289 | Â | Â | 0.4268 |
 I | 3 (1.0%) | 9 (1.4%) |  | 2 (1.0%) | 9 (2.2%) |  |
 II | 121 (41.4%) | 294 (45.4%) |  | 95 (47.3%) | 206 (51.2%) |  |
 III | 77 (26.4%) | 181 (28.0%) |  | 52 (25.9%) | 95 (23.6%) |  |
 Missing | 91 (31.2%) | 163 (25.2%) |  | 52 (25.9%) | 92 (22.9%) |  |
Nodal status, n (%) | Â | Â | 0.0046 | Â | Â | 0.9049 |
 N0 | 141 (48.3%) | 284 (43. 9%) |  | 103 (51.2%) | 202 (50.3%) |  |
 N1 | 80 (27.4%) | 184 (28.4%) |  | 69 (34.3%) | 202 (50.3%) |  |
 N2 | 22 (7.5%) | 89 (13.8%) |  | 19 (9.5%) | 36 (9.0%) |  |
 N3 | 12 (4.1%) | 58 (9.0%) |  | 10 (5.0%) | 26 (6.5%) |  |
 Missing | 37 (12.7%) | 32 (5.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
Tumor size, n (%) | Â | Â | 0.3915 | Â | Â | 0.4213 |
 T1 | 130 (44.5%) | 268 (41.4%) |  | 97 (48.3%) | 182 (45.3%) |  |
 T2 | 105 (36.0%) | 277 (42.8%) |  | 81 (40.3%) | 179 (44.5%) |  |
 T3 | 7 (2.4%) | 16 (2.5%) |  | 7 (3.5%) | 8 (2.0%) |  |
 T4 | 1 (0.3%) | 5 (0.8%) |  | 1 (0.5%) | 1 (0.3%) |  |
 Missing | 49 (16.8%) | 81 (12.5%) |  | 15 (7.5%) | 32 (8.0%) |  |
Molecular subtype, n (%) | Â | Â | 0.2054 | Â | Â | 0.7747 |
 Luminal A | 56 (19.2%) | 91 (14.1%) |  | 40 (19.9%) | 76 (18.9%) |  |
 Luminal B | 141 (48.3%) | 317 (49.0%) |  | 126 (62.7%) | 261 (64.9%) |  |
 HER2+ | 32 (11.0%) | 76 (11.8%) |  | 20 (10.0%) | 43 (10.7%) |  |
 BASAL-LIKE | 17 (5.8%) | 51 (7.9%) |  | 15 (7.5%) | 22 (5.5%) |  |
 Missing | 46 (15.8%) | 112 (17.3%) |  | 0 (0.0%) | 0 (0.0%) |  |
Ki-67 expression, n (%) | Â | Â | 0.3344 | Â | Â | 0.2419 |
  < 20% | 65 (22.3%) | 122 (18.9%) |  | 37 (18.4%) | 93 (23.1%) |  |
  ≥ 20% | 174 (59.6%) | 388 (60.0%) |  | 125 (62.2%) | 242 (60.2%) |  |
 Missing | 53 (18.2%) | 137 (21.2%) |  | 39 (19.4%) | 67 (16.7%) |  |